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Solid Oral Dosage Form Manufacturing Using 
Injection Moulding 
Overview:
Injection Moulding (IM):
Aim: to produce a solid oral dosage form that is both immediate release and has a homogeneous API dispersion
Powder blends Hot Melt Extrusion Extrudate Injection Moulding Dosage forms
Dissolution Profiles:
 Injection of molten material under pressure
 Product cools in mould then removed
 Commonly used for
 ? Packaging
 ? Biomedical devices
 Create solid oral dosage forms
 Makes use of polymers
 Dosage shape dependent on mould design
 Injection parameters
 ? Injection pressure
 ? Cylinder temperature
 ? Mould temperature
 ? Post-injection pressure
Conclusion & Future Work:
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Advantages Disadvantages
Scalable Stability issues
Drug in amorphous form Degradation of materials
Potential for continuous 
manufacture
Use of polymers can hinder 
drug release
Dosage unit shape can be 
designed
Mould design not easy and 
quick to alter
Solvents not required
Figure 1: Dosage forms produced using HME-IM using the polymer affinisol and paracetamol (PCM)
concentrations 5, 10, 20 and 50% (left to right), followed by 50% PCM formulation which recrystallised during
storage
Effects of Disintegrant type on Disintegration when using BCS II drug:
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Dissolution profiles for Paracetamol: Affinisol ? formulations
5%PCM-powder mix 5%PCM-HME 10%PCM-Powder Mix
10%PCM-HME 20%PCM-Powder Mix 20%PCM-HME
50%PCM-Powder Mix 50%PCM-HME Complete Release
Immediate Release
Figures 2 (left) shows the XRD results for dosage forms containing 50% paracetamol measured 1 week post
manufacture and after the colour changed to white 4 weeks later. The diffractograms on the top show that
both the dosage forms manufactured using IM and HME-IM (blue and red respectively) contain no distinctive
peaks associated with powder paracetamol (black) suggesting that the drug is amorphous.
Figure 3 (right) shows the DSC curves for samples of the same formulation (before and after the colour
change). Both brown dosage forms (top) observe solid-solid transition events around 91-96 °C that do not
appear in the DSC traces for the white dosage forms (bottom). As the XRD results suggest the white dosage
forms contain crystalline paracetamol it can be assumed that the heightened temperatures during DSC analysis
accelerate the transition from amorphous to crystalline material observed after 4 weeks storage.
The XRD and DSC traces for formulations containing 5, 10 and 20% paracetamol are not shown however they
suggest the drug is amorphous and remains so after 4 weeks storage time.
Figure 4 shows the dissolution
profiles for Affinisol ? dosage forms
produced from IM only and HME-IM
containing 5, 10, 20 & 50% PCM.
The data suggests that the polymer
due to ŝƚ ?Ɛslowly eroding properties
hinders drug release.
It is also evident that using HME
prior to IM is required in order to
control the resulting dosage.
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Figure 5 shows the contour maps produced using a DoE approach to analyse the effect of disintegrant type and
concentration on the mass remaining of strands consisting of Affinisol ? and BCS II drug. The results show that
the most influencing factor is API content. For all disintegrants a low drug concentration produced the smallest
mass remaining. There seems to be no significant effect on mass remaining caused by disintegrant concentration
except for when a small natural disintegrating agent is used. This suggests that for these formulations small
natural molecules should be more effective disintegrating agents whereas larger molecules hinder disintegration
due to poorer solubility and greater entanglement within the polymer strands when molten.
 It is possible to load Affinisol ? with various drug concentrations however at 50% stability issues are
introduced
 Due to the slow eroding properties of polymers other agents are required to help facilitate drug release
 The disintegration agent analysis showed that small molecules are more effective at enhancing the
breakdown of the ĂĨĨŝŶŝƐŽů ? containing extruded filaments than larger polymers which hindered the
process.
 It can also be concluded that as the API used for that study was a BCS class II drug the concentration of
drug was the most important factor affecting mass remaining and not the concentration of disintegrating
agent
 Future work will continue looking at disintegrating agents focussing on small molecules. Dosage forms will
also be produced for each formulation using IM
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